FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980236331> ?p ?o ?g. }

• W2980236331 endingPage "519" @default.
• W2980236331 startingPage "505" @default.
• W2980236331 abstract "In SILIUS (NCT01214343), combination of sorafenib and hepatic arterial infusion chemotherapy did not significantly improve overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) compared with sorafenib alone. In this study, we explored the relationship between objective response by mRECIST and OS in the sorafenib group, in the combination group, and in all patients in the SILIUS trial.Association between objective response and OS in patients treated with sorafenib (n = 103) or combination (n = 102) and all patients (n = 205) were analyzed. The median OS of responders was compared with that of non-responders. Landmark analyses were performed according to objective response at several fixed time points, as sensitivity analyses, and the effect on OS was evaluated by Cox regression analysis with objective response as a time-dependent covariate, with other prognostic factors.In the sorafenib group, OS of responders (n = 18) was significantly better than that of non-responders (n = 78) (p < 0.0001), where median OS was 27.2 (95% CI, 16.0-not reached) months for responders and 8.9 (95% CI, 6.5-12.6) months for non-responders. HRs from landmark analyses at 4, 6, and 8 months were 0.45 (p = 0.0330), 0.37 (p = 0.0053), and 0.36 (p = 0.0083), respectively. Objective response was an independent predictor of OS based on unstratified Cox regression analyses. In the all patients and the combination group, similar results were obtained.In the SILIUS trial, objective response by sorafenib assessed by mRECIST is an independent prognostic factor for OS in patients with HCC." @default.
• W2980236331 created "2019-10-18" @default.
• W2980236331 creator A5012321425 @default.
• W2980236331 creator A5015271832 @default.
• W2980236331 creator A5025371497 @default.
• W2980236331 creator A5030763210 @default.
• W2980236331 creator A5032900701 @default.
• W2980236331 creator A5037963685 @default.
• W2980236331 creator A5043762552 @default.
• W2980236331 creator A5046656967 @default.
• W2980236331 creator A5054807384 @default.
• W2980236331 creator A5056173852 @default.
• W2980236331 creator A5062645991 @default.
• W2980236331 creator A5066924600 @default.
• W2980236331 creator A5067074178 @default.
• W2980236331 creator A5074112363 @default.
• W2980236331 creator A5076696174 @default.
• W2980236331 creator A5076725199 @default.
• W2980236331 creator A5083677685 @default.
• W2980236331 creator A5087133884 @default.
• W2980236331 creator A5089636709 @default.
• W2980236331 date "2019-01-01" @default.
• W2980236331 modified "2023-09-23" @default.
• W2980236331 title "Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial" @default.
• W2980236331 cites W1007890594 @default.
• W2980236331 cites W1481905020 @default.
• W2980236331 cites W1971837077 @default.
• W2980236331 cites W1994193851 @default.
• W2980236331 cites W1994513787 @default.
• W2980236331 cites W1997974607 @default.
• W2980236331 cites W2003610950 @default.
• W2980236331 cites W2019294726 @default.
• W2980236331 cites W2019595161 @default.
• W2980236331 cites W2020362401 @default.
• W2980236331 cites W2024802373 @default.
• W2980236331 cites W2032084645 @default.
• W2980236331 cites W2034712313 @default.
• W2980236331 cites W2046990725 @default.
• W2980236331 cites W2079586464 @default.
• W2980236331 cites W2094109552 @default.
• W2980236331 cites W2099169332 @default.
• W2980236331 cites W2110608811 @default.
• W2980236331 cites W2110643890 @default.
• W2980236331 cites W2110847259 @default.
• W2980236331 cites W2120079339 @default.
• W2980236331 cites W2151600653 @default.
• W2980236331 cites W2164090407 @default.
• W2980236331 cites W2195297470 @default.
• W2980236331 cites W2238432908 @default.
• W2980236331 cites W2277004004 @default.
• W2980236331 cites W2347052280 @default.
• W2980236331 cites W2414951782 @default.
• W2980236331 cites W2512061943 @default.
• W2980236331 cites W2568897093 @default.
• W2980236331 cites W2581205085 @default.
• W2980236331 cites W2745488932 @default.
• W2980236331 cites W2787358630 @default.
• W2980236331 cites W2795708663 @default.
• W2980236331 cites W2889646458 @default.
• W2980236331 cites W4239330499 @default.
• W2980236331 cites W4300577090 @default.
• W2980236331 doi "https://doi.org/10.1159/000503032" @default.
• W2980236331 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6883462" @default.
• W2980236331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31799207" @default.
• W2980236331 hasPublicationYear "2019" @default.
• W2980236331 type Work @default.
• W2980236331 sameAs 2980236331 @default.
• W2980236331 citedByCount "17" @default.
• W2980236331 countsByYear W29802363312020 @default.
• W2980236331 countsByYear W29802363312021 @default.
• W2980236331 countsByYear W29802363312022 @default.
• W2980236331 countsByYear W29802363312023 @default.
• W2980236331 crossrefType "journal-article" @default.
• W2980236331 hasAuthorship W2980236331A5012321425 @default.
• W2980236331 hasAuthorship W2980236331A5015271832 @default.
• W2980236331 hasAuthorship W2980236331A5025371497 @default.
• W2980236331 hasAuthorship W2980236331A5030763210 @default.
• W2980236331 hasAuthorship W2980236331A5032900701 @default.
• W2980236331 hasAuthorship W2980236331A5037963685 @default.
• W2980236331 hasAuthorship W2980236331A5043762552 @default.
• W2980236331 hasAuthorship W2980236331A5046656967 @default.
• W2980236331 hasAuthorship W2980236331A5054807384 @default.
• W2980236331 hasAuthorship W2980236331A5056173852 @default.
• W2980236331 hasAuthorship W2980236331A5062645991 @default.
• W2980236331 hasAuthorship W2980236331A5066924600 @default.
• W2980236331 hasAuthorship W2980236331A5067074178 @default.
• W2980236331 hasAuthorship W2980236331A5074112363 @default.
• W2980236331 hasAuthorship W2980236331A5076696174 @default.
• W2980236331 hasAuthorship W2980236331A5076725199 @default.
• W2980236331 hasAuthorship W2980236331A5083677685 @default.
• W2980236331 hasAuthorship W2980236331A5087133884 @default.
• W2980236331 hasAuthorship W2980236331A5089636709 @default.
• W2980236331 hasBestOaLocation W29802363311 @default.
• W2980236331 hasConcept C126322002 @default.
• W2980236331 hasConcept C143998085 @default.
• W2980236331 hasConcept C2777546739 @default.
• W2980236331 hasConcept C2778019345 @default.
• W2980236331 hasConcept C2778695046 @default.

• next